# GISEV Family Office

> GISEV Family Office is a VC fund in Lugano backing Health Care and Biotechnology. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Lugano, Switzerland
- Total investments: 8
- Last investment: Nov 2022
- Lead investor: 25%
- Last updated: Aug 2026
- Website: http://www.gisev.com/

GISEV Family Office is a investment firm.

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $11M–$40M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 6 | 75% |
| Biotechnology | 4 | 50% |
| Wellness | 3 | 38% |
| Therapeutics | 3 | 38% |
| Personal Health | 2 | 25% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 38% |
| Seed | 1 | 13% |
| Pre-Seed | 1 | 13% |
| Series B | 1 | 13% |
| Series C | 1 | 13% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 6 | 75% |
| Argentina | 1 | 13% |
| United Kingdom | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Bionaut Labs | Bionaut Labs revolutionizes the treatment of central nervous system disorders with its precision medicine treatment modality. By creating a new medical modality of remote-controlled micro-robots called Bionauts, the company can transform the way the biopharmaceutical industry develops treatments, allowing them to engineer the therapeutic index forefficacy and maintain safety.Bionaut Labs is focused on helping patients suffering from debilitating brain diseases who have few available treatment options. The anatomical targeting capabilities of the Bionaut platform make new therapeutics technologies such as gene therapy, CRISPR-Cas9, and oncolytic viruses viable in challenging clinical settings. | $43.2M | Series B | Nov 28, 2022 | http://www.bionautlabs.com |
| Revea | Revea is a us-based one-of-its-kind precision skincare company. | $6M | Seed | Apr 21, 2022 | https://www.myrevea.com/ |
| Syocin Biotech | Syocin Biotech is developing a synthetic biology platform for the redesign of natural existing biomolecules to precisely target plant bacterial pathogens that threaten world food availability. | $450K | Pre-Seed | Dec 30, 2021 | http://www.syocin.com/ |
| Seed Health | Seed Health is a microbial company that specializes in therapeutics, consumer health innovations, and environmental solutions. The company focuses on breakthrough discoveries in microbial sciences across a pipeline of novel therapeutics. It was founded by Ara Katz and Raja Dhir in 2017 and is headquartered in Venice, California. | $40M | Series A | Apr 21, 2021 | https://www.seed.com/ |
| Voy | Manual is a men’s health and well-being startup offering a suite of diagnostic tools and blood tests to offer data-driven health solutions. The company provides men with easy access to advice, free medical support, and the treatment choices they need to help them make proactive decisions about their wellbeing.Manual was founded in 2018 and isheadquartered in London, UK. | $30.2M | Series A | Mar 30, 2021 | https://www.manual.co/ |
| Solarea Bio | Solarea Bio is a biotech company that develops microbial therapeutics aimed to treat indications derived from chronic inflammation to aid human health.It specializes in the research and development of therapeutics that are derived from natural sources and are aimed to treat indications derived from chronic inflammation, enabling hospitals toprovide medicinal drugs for improved quality of life. The company generates a large database of the complete genomic sequences of microbes derived from healthy foods. Using computational approaches, Solarea generates synergistic combinations of bacteria, fungi, and prebiotic fibers with powerful anti-inflammatory capabilities to address specific chronic conditions that afflict large numbers of people. These have been validated in-vitro and in-vivo in preclinical mouse models. Its first application aims to aid in the dietary management of the metabolic processes that cause osteopenia and osteoporosis in postmenopausal women. This provides a nature-based solution to improving women’s health and well-being.The Cambridge, Massachusetts-based company was established in 2017 by Eric Schott, Gerardo Toledo, and Jillian DeWalt. | $11.2M | Series A | Oct 19, 2020 | https://solareabio.com |
| Symbiome | Symbiome offers skincare as nature intended solution which is scientifically and intentionally formulated using ancestral ingredients. It was founded in 2017 and is headquartered in San Francisco, California. | $15M | Venture - Series Unknown | Sep 14, 2020 | https://www.symbiome.com |
| Elysium | Elysium Health offers health products built with science such as dietary supplements and anti-aging drugs. It seeks to solve challenges in health with science, to help people live healthier and longer lives. It works directly with the scientists, clinicians, and health professionals around the world to identify and develop the natural compounds.Its product is a proprietary formulation of two ingredients designed to support long-term well-being at the cellular level. | $40M | Series C | Dec 23, 2019 | http://www.elysiumhealth.com |

8 of 8 investments shown.

## Co-investors
- [Bold Capital Partners](https://shizune.co/investors/profile/bold-capital) — VC Fund, 3 deals together
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund, 2 deals together
- [Khosla Ventures](https://shizune.co/investors/profile/khosla-ventures) — VC Fund, 2 deals together
- [Upfront Ventures](https://shizune.co/investors/profile/upfront-ventures) — VC Fund, 2 deals together
- [Waldencast](https://shizune.co/investors/profile/waldencast) — VC Fund, 2 deals together
- [8VC](https://shizune.co/investors/profile/8vc) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Newtopia VC](https://shizune.co/investors/profile/newtopia-vc) — VC Fund
- [NXTP Ventures](https://shizune.co/investors/profile/nxtp-ventures) — VC Fund
- [Alaya Capital](https://shizune.co/investors/profile/alaya-capital) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Argentina](https://shizune.co/investors/biotechnology-investors-argentina)
- [Biotechnology VC Funds in Argentina](https://shizune.co/investors/biotechnology-vc-funds-argentina)
- [Biotech Investors in Argentina](https://shizune.co/investors/biotech-investors-argentina)
- [Biotech VC Funds in Argentina](https://shizune.co/investors/biotech-vc-funds-argentina)

## FAQ

### What does GISEV Family Office invest in?

GISEV Family Office invests primarily in Health Care, Biotechnology and Wellness startups, most often at Series A and Seed stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is GISEV Family Office's check size?

GISEV Family Office typically joins rounds of $11M–$40M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds GISEV Family Office participates in.

### When did GISEV Family Office last invest?

The most recent investment recorded for GISEV Family Office closed in Nov 2022. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co